Novartis Gets FDA Approval for Use of Pluvicto Against Prostate Cancer

 Novartis said the U.S. Food and Drug Administration has approved the use of Pluvicto against a certain type of prostate cancer.

The drug maker said Friday that the FDA green-lit the use of Pluvicto to treat patients with prostate cancer that is metastatic and castration-resistant, also known as mCRPC.

The expanded indication approximately triples the number of patients eligible to receive Pluvicto, Novartis said.

The FDA's decision is based on results of the Phase III PSMAfore trial, in which Pluvicto cut the risk of radiographic progression or death by 59% compared to another therapy.

More than 35,000 men die from prostate cancer each year, according to figures provided by Novartis.

https://www.morningstar.com/news/dow-jones/202503289091/novartis-gets-fda-approval-for-use-of-pluvicto-against-prostate-cancer